Pharmaceutical compositions and methods
AssigneePop Test Oncology LLC
InventorsRandice Lisa Altshul, Neil David Thiese, Andreas J. Kesel, Myron Rapkin, Rebecca O'Brien, Anthony Arment
Life of this patent
Estimating the term…
Abstract
This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
Claims15
A pharmaceutical composition comprising:
- at least one active agent selected from the group consisting of PT150, PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
- optionally, at least one auxiliary agent selected from the group consisting of opiates.
A method of treatment, comprising:
- selecting a patient in need of treating or preventing a condition selected from the group consisting of nicotine, opioids, methamphetamine, and/or alcohol addiction;
- nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety;
- and nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms;
- and
- administering to the patient in need of treating or preventing the condition an effective amount of at least one active agent selected from the group consisting of PT150, PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
A method of treatment, comprising:
- selecting a patient in need of treating or preventing a condition selected from the group consisting of nicotine, opioids, methamphetamine, and/or alcohol addiction;
- nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety;
- and nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms;
- administering a composition comprising:
- i) a therapeutic selected from the group consisting of PT150, PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
- ii) at least one additional therapeutic agent(s) selected from the group consisting of anxiolytics, antidepressants, neuroleptics, or other psychotropic medications and combinations thereof;
- and
- iii) at least one pharmaceutically acceptable carrier, wherein the therapeutic and the at least one additional therapeutic agents are each present in an amount which, in combination, is a therapeutically effective amount for treating or preventing the condition.
A method of treating or preventing nicotine, opioids, methamphetamine, and/or alcohol addiction, nicotine, opioids, methamphetamine, and/or alcohol addiction induced anxiety, and/or nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms in a patient, comprising the steps of:
- a) obtaining a test sample from the patient using a test sample collection unit;
- b) combining said test sample with a buffering system to form a mixture in a reaction unit;
- c) measuring a parameter of the mixture to determine a blank measurement;
- d) combining said test sample and buffer mixture with a labeled ligand which binds cortisol in the reaction unit to produce an assay solution;
- or combining said test sample and buffer mixture and delivering it to a carrier containing a labeled ligand which binds cortisol in the reaction unit to produce an assay immobilized complex;
- e) measuring a parameter of said assay solution or complex;
- f) comparing the measurement of the assay solution relative to the blank measurement;
- g) determining the patient's circulating cortisol levels based on the change of the measurement;
- h) comparing the measured cortisol levels to a predetermined reference range cortisol levels, wherein when the level of cortisol is elevated relative to the predetermined reference range, then the patient has elevated cortisol, and thus is suitable for GCR (glucocorticoid receptor) antagonist therapy;
- and
- i) when the patient is suitable the therapeutic is selected from the group consisting of PT150, PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof;
- thereby treating or preventing nicotine, opioids, methamphetamine, and/or alcohol addiction, nicotine, opioids, methamphetamine,
- and/or alcohol addiction induced anxiety, and/or nicotine, opioids, methamphetamine, and/or alcohol withdrawal symptoms in the patient.
Dependencies are inferred from the claim text.